A new biomarker might possibly furnish new clues required to develop a diagnostic tool for hypoglycemia-associated autonomic failure (HAAF), an LSU Pennington Biomedical Research Center study found. There is no current objective diagnostic device for this life-threatening condition, if unchecked.
Johnson & Johnson is moving out from the diabetes business and sold its Calibra product (marketed as OneTouch Via, but never launched) to a 10-year-old company named CeQur, which was already working on a similar insulin-delivery wearable. The terms and conditions of this deal have not yet been yet disclosed, but CeQur has attained an exclusive worldwide license for this technology.
On Tuesday the analysis results of a yearlong comparative study of hospital admission rates between diabetes patients using insulin pumps and those taking multiple daily injections of insulin were released by Medtronic (NYSE: MDT) and UnitedHealthcare (NYSE: UNH).
This Cardiogram work was based on Framingham Heart Study 2015, where the resting and variable heart rate significantly predicted hypertension and diabetes. This prototype helped the cardiogram research team to use the Apple Watch’s heart rate sensor for accurate diabetes predictions.
According to the WHO statistical report, around 1.5 million deaths are caused due to diabetes worldwide. With these statistics in mind, a research team from the University of Copenhagen and Aarhus University in Denmark conducted research on diabetes patients.
Administration of two doses of BCG with a duration of four weeks apart can normalize the blood sugar levels for up to eight years. Tumor necrosis factor (TNF) is a protein that eliminates improper immune cells that destroy pancreatic islets, involved in immune production. But the administration of BCG can ultimately regulate T cells and boost TNF production.
Medtronic, a medical technology company, and AI-powered personalized nutrition platform Nutrino, have entered into a partnership. The FoodPrint Report technology of Nutrino is slated to be integrated into the iPro2myLog app of Medtronic, a platform which offers continuous glucose monitor enabling users to gain critical insights into their glucose levels.
U.S. Food and Drug Administration officially approved the weekly injection of semaglutide under the brand name of Ozempic. This therapy along with healthy diet and exercise would improve glycemic control in adults with type 2 diabetes. The side effects of semaglutide was found to be mild or moderate nausea.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.